reference/8771853

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8771853

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	505
issn	2159-8274 2159-8290
issueIdentifier	5
pageRange	494-505
publicationName	Cancer Discovery
startingPage	494
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e01b2377fafe8e7c7349c9fbe5f031a9 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e57a2df28cd3d691c9ebea9a73b49d7b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e3c18600b59b2612497bf6b95256a2d6 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_fc4669a0a15a65d0efcdbdee2402d1a1 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5a869a9e68bbc6d16a484a5702aedb79 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7e218262a6f9484862cb42e5e7de1b80 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d8f56c26b0165ef524a406a80cb9a500 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f89ededd6844d10ff1de5e6ee44ff870 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f44e02fcf9fa27484f2fa88838529c69 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_69c0a07d2d9f1fd2c4ef1988951f4c51 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_c72296477bdb446985bbfad35aeb256c http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a59d520510c3e536ca3f3a20808b7bc6
bibliographicCitation	Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. 2017 Apr 30;7(5):494–505. doi: 10.1158/2159-8290.cd-16-1049.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3270ad83aaa01869ac196ebec738e299 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_375fe23946d010d73613af0be0a11010 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0b05fbeb517ed69d684936317289784 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53f00a0ed2a6adaed630444f9964412a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b29e00038637dcb43377025ddd6e101 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa6ee2c8d8363dd7f1e32952cfa96bb2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_faef94c30bbd6538db8902874130c042 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3892cbc2e06addf21f959fc3262b5749 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a19375ed33535b91b59a1e3fe5649011 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_afffd2536cdc69f1cc33c663f7106dc7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cedf556edc617597393bdb8e405e20ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37ff9d4d9c0db6c4667d68bc36a4c4c5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4d511e8db986411a72dba055c25ea2e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c94a6c2ca3638f2f97f59b5fded5bc96 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0663-6216 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8330de1c7eeb3d506812cbe1f6476e8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_64400508ba187e308bf0fe0520784fe0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0100dbedc40036e36db75c7e3f85d526 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_666e7f32273b83a3fb5105b3afb383b3
date	2017-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/28193779 https://pubmed.ncbi.nlm.nih.gov/PMC5413413 https://doi.org/10.1158/2159-8290.cd-16-1049
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39259 https://portal.issn.org/resource/ISSN/2159-8274 https://portal.issn.org/resource/ISSN/2159-8290
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia
discusses	http://id.nlm.nih.gov/mesh/M0002060 http://id.nlm.nih.gov/mesh/M000607958 http://id.nlm.nih.gov/mesh/M0464092 http://id.nlm.nih.gov/mesh/M0017909 http://id.nlm.nih.gov/mesh/M0549624 http://id.nlm.nih.gov/mesh/M000635157 http://id.nlm.nih.gov/mesh/M0021908 http://id.nlm.nih.gov/mesh/M0190176 http://id.nlm.nih.gov/mesh/M0011751 http://id.nlm.nih.gov/mesh/M0468901 http://id.nlm.nih.gov/mesh/M0006678 http://id.nlm.nih.gov/mesh/M0000964
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D007521Q000235 http://id.nlm.nih.gov/mesh/D000971Q000494 http://id.nlm.nih.gov/mesh/D058990Q000379 http://id.nlm.nih.gov/mesh/D004268Q000235 http://id.nlm.nih.gov/mesh/D015470Q000188 http://id.nlm.nih.gov/mesh/D011518Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D014227Q000494 http://id.nlm.nih.gov/mesh/D051379 http://id.nlm.nih.gov/mesh/D044127Q000187 http://id.nlm.nih.gov/mesh/D000631Q000494 http://id.nlm.nih.gov/mesh/D001374Q000494 http://id.nlm.nih.gov/mesh/D015398Q000187 http://id.nlm.nih.gov/mesh/D008817 http://id.nlm.nih.gov/mesh/D009154 http://id.nlm.nih.gov/mesh/D049308 http://id.nlm.nih.gov/mesh/D051941Q000235 http://id.nlm.nih.gov/mesh/D019175Q000187 http://id.nlm.nih.gov/mesh/D015470Q000235
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID89683805 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9731 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9444 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c09812e6766ef2f1e11efd56052399b5 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9e97a47eb9e6c78b61149c74e7330d8f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_45bd205c63f9c9cfc7d5ba167cb355f0 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.1.1.37 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11431 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8300

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID269951 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID214133 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14255

Total number of triples: 96.